80 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis and evaluation of geldanamycin-estradiol hybrids.
Sloan-Kettering Institute For Cancer Research
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Infinity Pharmaceuticals
Design, Synthesis, and Biological Evaluation of Chiral-Proline Derivatives as Novel HSP90 Inhibitors.
Dezhou University
Isoxazole compounds: Unveiling the synthetic strategy, in-silico SAR & toxicity studies and future perspective as PARP inhibitor in cancer therapy.
Guru Ghasidas Vishwavidyalaya (A Central University)
Lanosterol 14α-Demethylase (CYP51)/Heat Shock Protein 90 (Hsp90) Dual Inhibitors for the Treatment of Invasive Candidiasis.
Second Military Medical University (Naval Medical University)
Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Knight Cancer Institute
New Class of Hsp90 C-Terminal Domain Inhibitors with Anti-tumor Properties against Triple-Negative Breast Cancer.
University of Ljubljana
Discovery of three-dimensional bicyclo[3.3.1]nonanols as novel heat shock protein 90 inhibitors.
Tokyo Institute of Innovative Research
A silicon-containing aryl/penta-1,4-dien-3-one/amine hybrid exhibits antiproliferative effects on breast cancer cells by targeting the HSP90 C-terminus without inducing heat-shock response.
Yunnan University
Design, synthesis, and biological evaluation of novel dual inhibitors of heat shock protein 90/mammalian target of rapamycin (Hsp90/mTOR) against bladder cancer cells.
Sichuan University
1,2,4-Amino-triazine derivatives as pyruvate dehydrogenase kinase inhibitors: Synthesis and pharmacological evaluation.
University of Palermo
Isoxazole ring as a useful scaffold in a search for new therapeutic agents.
Wroclaw University
Anticancer fungal natural products: Mechanisms of action and biosynthesis.
Sun Yat-Sen University
β-Lactams as promising anticancer agents: Molecular hybrids, structure activity relationships and potential targets.
Beijing University of Chinese Medicine
Computational methods-guided design of modulators targeting protein-protein interactions (PPIs).
Shanghai Jiao Tong University
Natural heat shock protein 90 inhibitors in cancer and inflammation.
Oswaldo Cruz Foundation
Recent advances toward the development of Hsp90 C-terminal inhibitors.
University of Notre Dame
Structure, Function, and Inhibitors of the Mitochondrial Chaperone TRAP1.
Ewha Womans University
Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.
South China University of Technology
Species-Selective Targeting of Fungal Hsp90: Design, Synthesis, and Evaluation of Novel 4,5-Diarylisoxazole Derivatives for the Combination Treatment of Azole-Resistant Candidiasis.
Shenyang Pharmaceutical University
Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer.
Fujian Medical University (Fmu)
Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
Second Military Medical University
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Indian Institute of Technology (B.H.U.)
Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
Memorial Sloan-Kettering Cancer Center
Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Conforma Therapeutics
Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures.
Ribotargets
Synthesis of novel fluorescent probes for the molecular chaperone Hsp90.
Memorial Sloan-Kettering Cancer Center
Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.
Taipei Medical University
Discovery of novel Hsp90 C-terminal domain inhibitors that disrupt co-chaperone binding.
University of Auckland
Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core.
China Pharmaceutical University
Using NMR to identify binding regions for N and C-terminal Hsp90 inhibitors using Hsp90 domains.
University of New South Wales
Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
Mansoura University
Discovery of novel heat shock protein (Hsp90) inhibitors based on luminespib with potent antitumor activity.
Seoul National University
Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
Fujian Medical University (Fmu)
From Bacteria to Cancer: A Benzothiazole-Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C-Terminal Inhibition.
The University of Notre Dame
Enzymatic biosynthesis and biological evaluation of novel 17-AAG glucoside as potential anti-cancer agents.
Bengbu Medical College
p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators.
China Pharmaceutical University
Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.
Chinese Academy of Sciences
High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.
Jiangsu Normal University
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
China Pharmaceutical University
Identification of Novel Resorcinol Amide Derivatives as Potent and Specific Pyruvate Dehydrogenase Kinase (PDHK) Inhibitors.
Korea University
Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.
China Pharmaceutical University
Clinical candidates modulating protein-protein interactions: The fragment-based experience.
Taros Chemicals
Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design.
Istituto Di Chimica Del Riconoscimento Molecolare
C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Heinrich Heine University D£Sseldorf
Optimization and bioevaluation of Cdc37-derived peptides: An insight into Hsp90-Cdc37 protein-protein interaction modulators.
China Pharmaceutical University
Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.
Montclair State University
Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
University of Arizona
Synthesis and biological activities of a new class of heat shock protein 90 inhibitors, designed by energy-based pharmacophore virtual screening.
University of Palermo
3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues.
The University of Kansas
Discovery of (2S)-1-[4-(2-{6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9H-purin-9-yl}ethyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor.
Myrexis
Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone.
Pfizer
Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
Astex Therapeutics
Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.
University of Milan
Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues.
The University of Kansas
Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone.
Pfizer
Discovery of 5-substituted 2-amino-4-chloro-8-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-7,8-dihydropteridin-6(5H)-ones as potent and selective Hsp90 inhibitors.
Poniard Pharmaceuticals
Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents.
Serenex
Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold.
The University of Kansas
Synthesis and SAR study of N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl)phenyl)-arylsulfonamides: heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in vitro assay.
Emory University
Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling.
Emory University
Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (HSP90).
National University of Singapore
Ligand Desolvation Steers On-Rate and Impacts Drug Residence Time of Heat Shock Protein 90 (Hsp90) Inhibitors.
University of Vienna
Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis.
China Pharmaceutical University
Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
China Pharmaceutical University
Synthesis and pharmacological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline analogues) as D1 and D2 dopamine receptor ligands.
Purdue University